{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:22:25Z","timestamp":1783459345302,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,20]],"date-time":"2027-06-20T00:00:00Z","timestamp":1813449600000},"content-version":"am","delay-in-days":323,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.diabres.2026.113377","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:30:22Z","timestamp":1781566222000},"page":"113377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease: a Japan Chronic Kidney Disease Database Extension analysis"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0705-5923","authenticated-orcid":false,"given":"Takanori","family":"Nagahiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3020-7526","authenticated-orcid":false,"given":"Masaaki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Kanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Nagasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Tsuruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.diabres.2026.113377_b0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41574-025-01171-3","article-title":"Mechanisms of diabetic kidney disease and established and emerging treatments","volume":"22","author":"Martinez Leon","year":"2026","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"10.1016\/j.diabres.2026.113377_b0010","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1016\/j.diabres.2026.113377_b0015","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabres.2026.113377_b0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113377_b0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.diabres.2026.113377_b0030","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.diabres.2026.113377_b0035","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.diabres.2026.113377_b0040","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2026.113377_b0045","first-page":"S179","article-title":"10. Cardiovascular disease and risk management: Standards of Care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"18","key":"10.1016\/j.diabres.2026.113377_b0050","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.jacc.2020.09.004","article-title":"Effects of canagliflozin on amino-terminal pro-B-type natriuretic peptide: implications for cardiovascular risk reduction","volume":"76","author":"Januzzi","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.diabres.2026.113377_b0055","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.1038\/s41598-020-64123-z","article-title":"J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan","volume":"10","author":"Nakagawa","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.diabres.2026.113377_b0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3414\/ME10-01-0015","article-title":"SS-MIX: a ministry project to promote standardized healthcare information exchange","volume":"50","author":"Kimura","year":"2011","journal-title":"Methods Inf Med"},{"issue":"1","key":"10.1016\/j.diabres.2026.113377_b0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1197\/jamia.M3299","article-title":"Development of an electronic public health case report using HL7 v2.5 to meet public health needs","volume":"17","author":"Rajeev","year":"2010","journal-title":"J Am Med Inform Assoc"},{"issue":"2","key":"10.1016\/j.diabres.2026.113377_b0070","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.2196\/medinform.5275","article-title":"A querying method over RDF-ized health level seven v2.5 messages using life science knowledge resources","volume":"4","author":"Kawazoe","year":"2016","journal-title":"JMIR Med Inform"},{"key":"10.1016\/j.diabres.2026.113377_b0075","first-page":"1050","article-title":"Development of unified lab test result master for multiple facilities","volume":"216","author":"Kume","year":"2015","journal-title":"Stud Health Technol Inform"},{"issue":"1","key":"10.1016\/j.diabres.2026.113377_b0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","article-title":"Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates","volume":"56","author":"Horio","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.diabres.2026.113377_b0085","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.2337\/dc21-1081","article-title":"Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the japan chronic kidney disease database","volume":"44","author":"Nagasu","year":"2021","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.diabres.2026.113377_b0090","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ehj.2004.07.038","article-title":"Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure","volume":"25","author":"Gackowski","year":"2004","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.diabres.2026.113377_b0095","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1253\/circj.CJ-25-0002","article-title":"JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure","volume":"89","author":"Kitai","year":"2025","journal-title":"Circ J"},{"issue":"15","key":"10.1016\/j.diabres.2026.113377_b0100","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","article-title":"N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients","volume":"110","author":"Bettencourt","year":"2004","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.diabres.2026.113377_b0105","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"21","key":"10.1016\/j.diabres.2026.113377_b0110","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diabres.2026.113377_b0115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.diabres.2026.113377_b0120","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2026.113377_b0125","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diabres.2026.113377_b0130","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2026.113377_b0135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.diabres.2026.113377_b0140","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.diabres.2026.113377_b0145","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"5s","key":"10.1016\/j.diabres.2026.113377_b0150","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"issue":"1 Suppl 1","key":"10.1016\/j.diabres.2026.113377_b0155","first-page":"S266","article-title":"13. Older adults: standards of care in diabetes-2025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2026.113377_b0160","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1111\/dom.15611","article-title":"Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: the Japan Chronic Kidney Disease Database","volume":"26","author":"Kanaoka","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"10.1016\/j.diabres.2026.113377_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12226993","article-title":"Reasons for discontinuing treatment with sodium-glucose cotransporter 2 inhibitors in patients with diabetes in real-world settings: the KAMOGAWA-A study","volume":"12","author":"Saijo","year":"2023","journal-title":"J Clin Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:10:04Z","timestamp":1783458604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726002974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S0168822726002974"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113377","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease: a Japan Chronic Kidney Disease Database Extension analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113377","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113377"}}